Duke University Medical Center, Bone Marrow Transplant Program, Durham, North Carolina, USA.
Address correspondence to: Nelson Chao, Hematological Malignancies and Cellular Therapy/BMT, 2400 Pratt St., Suite 9100, Box 3961, Durham, North Carolina 27710, USA. Phone: 919.668.1010; Fax: 919.668.1091; E-mail: firstname.lastname@example.org.
First published May 15, 2013 - More info
Current strategies to suppress graft-versus-host disease (GVHD) also compromise graft-versus-tumor (GVT) responses. Furthermore, most experimental strategies to separate GVHD and GVT responses merely spare GVT function without actually enhancing it. We have previously shown that endogenously expressed TNF-related apoptosis-inducing ligand (TRAIL) is required for optimal GVT activity against certain malignancies in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). In order to model a donor-derived cellular therapy, we genetically engineered T cells to overexpress TRAIL and adoptively transferred donor-type unsorted TRAIL+ T cells into mouse models of allo-HSCT. We found that murine TRAIL+ T cells induced apoptosis of alloreactive T cells, thereby reducing GVHD in a DR5-dependent manner. Furthermore, murine TRAIL+ T cells mediated enhanced in vitro and in vivo antilymphoma GVT response. Moreover, human TRAIL+ T cells mediated enhanced in vitro cytotoxicity against both human leukemia cell lines and against freshly isolated chronic lymphocytic leukemia (CLL) cells. Finally, as a model of off-the-shelf, donor-unrestricted antitumor cellular therapy, in vitro#x02013;generated TRAIL+ precursor T cells from third-party donors also mediated enhanced GVT response in the absence of GVHD. These data indicate that TRAIL-overexpressing donor T cells could potentially enhance the curative potential of allo-HSCT by increasing GVT response and suppressing GVHD.
Arnab Ghosh, Yildirim Dogan, Maxim Moroz, Amanda M. Holland, Nury L. Yim, Uttam K. Rao, Lauren F. Young, Daniel Tannenbaum, Durva Masih, Enrico Velardi, Jennifer J. Tsai, Robert R. Jenq, Olaf Penack, Alan M. Hanash, Odette M. Smith, Kelly Piersanti, Cecilia Lezcano, George F. Murphy, Chen Liu, M. Lia Palomba, Martin G. Sauer, Michel Sadelain, Vladimir Ponomarev, Marcel R.M. van den Brink
There is a ying/yang to most biological therapies, and the balance of efficacy versus toxicity is delicate and sometimes difficult to achieve in favor of the patients. When the therapeutic window is wide, these therapies can be used in the majority of patients, but when the therapeutic window is narrow, the decision to proceed must be carefully balanced with a thoughtful risk-benefit analysis. In this issue of the JCI, Ghosh et al. tackle one of the major obstacles in hematopoietic cell transplantation (HCT) technology: balancing the beneficial antitumor effect with the harmful anti-host effect.
HCT describes the process of introducing new donor cells into a host, most often to treat hematological malignancy. The aim of treatment is to replace the damaged hematopoietic cells with normal stem cells, and requires the rebuilding of a new immune system, since the original needs to be destroyed to allow for donor engraftment. The new immune system can recognize virulent microbial agents, alloantigens, and tumor-specific antigens, leading to the beneficial graft-versus-tumor/leukemia (GVL) effect. On the other hand, donor T cell recognition of host antigens can result in graft-versus-host disease (GVHD) (1). The occurrence of GVHD is the single greatest obstacle to successful allogeneic stem cell transplantation, and the prevention of GVHD while preserving GVL is the holy grail of research in this field.
Several early experimental models testing the potential for GVL by allogeneic cells failed because of the induction of GVHD (2, 3). As van Bekkum and de Vries described the state of the field in 1967, “It seems to be extremely difficult to induce that precise degree of graft versus host reactivity which will kill the leukaemic cells but which is at the same time mild enough to allow survival of the host” (4). By the mid-1970s, the clinical data demonstrated a lower leukemia relapse rate, and a significant survival advantage was associated with the development of GVHD (5). Thus, the understanding of the basic biology of T cells was still insufficient to balance GVHD and GVL.
In this issue of the JCI, Ghosh et al. present tantalizing data to suggest that it may be possible to actually enhance GVL without increasing the risk of developing GVHD (6). This group previously demonstrated that TNF-related apoptosis-inducing ligand (TRAIL) is required for optimal GVL activity (7). In the current article, Ghosh et al. genetically engineered T cells to overexpress TRAIL and used these cells in adoptive transfer experiments (6). As expected, they observed that TRAIL+ T cells were highly active in vitro and in vivo in a murine model. Surprisingly, however, they also found that these same cells led to reduced GVHD through the induction of apoptosis of alloreactive T cells (fratricide) and of host APCs, which upregulate the TRAIL receptor, death receptor 5 (DR5), following radiation (Figure 1). Further, using mice infected with lymphocytic choriomeningitis virus (LCMV), they found that TRAIL+ T cells do not significantly impair antiviral responses. These data suggest that this population of TRAIL+ T cells is unique in that the cells can remove the T cells that are responsible for GVHD through fratricide, but they do not kill off the T cells that convey protection from viral infections. Ghosh et al. further suggest that these TRAIL+ T cells could be used “off the shelf” through a third-party donor and demonstrate that human TRAIL+ T cells have enhanced cytotoxicity against several freshly isolated chronic lymphocytic leukemia cells.
The promise of TRAIL+ T cells in allo-HCT. The new sheriff (TRAIL+ T cells) kill off DR5+ cells while sparing other T cells, thus achieving the prevention of GVHD without loss of GVL.
Like all good articles, this work raises interesting questions. The first caveat to keep in mind is that these are data from murine models. While this is an important first step, human T cell biology may differ substantially, and more work will need to be done before this advance is translated to patient therapy.
It will be interesting and important to determine how these TRAIL+ T cells traffic differently from other populations, since the luciferase images suggest that they do not pool in the gut at day 7 compared with wild-type, luciferase+, or GFP+ cells. It is possible that TRAIL+ T cells are deleting the gut APCs, resulting in reduced T cell activation.
Furthermore, it is difficult to explain why these TRAIL+ T cells do not suppress an antiviral response in a similar manner to the alloresponse. The authors suggest that this may be related to increased cytotoxicity of the TRAIL+ T cells (6), but the molecular details of this remain to be elucidated. Last, it would be useful to know how long these cells would persist in vivo, as continued survival of TRAIL+ T cells would result in suppressed immune responses if every activated T cell were eliminated.
We are now entering an exciting era in which adoptive cellular therapies are more commonplace, and the use of engineered T cells is expanding. The approach described in this article of manipulating TRAIL expression before transplantation may provide a unique opportunity to target tumor cells without inducing GVHD. As mentioned above, cells overexpressing TRAIL could also be quite useful as an “off-the-shelf” third-party infusion following lymphodepletion in a patient, resulting in GVL activity during the lymphopenic period, followed by rejection of the allogeneic TRAIL+ cells after recovery of host immunity. Indeed, the work by Ghosh et al. (6) suggests that TRAIL+ T cells could exert their antitumor effects during this period of lymphodepletion, ridding the patient of the malignancy without altering their ability to fight viral infections. This manuscript advances the field of cellular therapy by documenting the potential of separating GVHD from GVL: the prevention of GVHD not only without loss of GVL, but actual enhancement of GVL.
Conflict of interest: The author has declared that no conflict of interest exists.
Reference information: J Clin Invest. 2013;123(6):2362–2363. doi:10.1172/JCI69909.
See the related article at Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.